Are you Dr. Jiang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 29 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1717 13th St
Suite 300
Everett, WA 98201Phone+1 425-297-5500Fax+1 425-297-5514
Summary
- Dr. Peter Jiang, MD is an oncologist in Everett, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with Providence Regional Medical Center Everett, EvergreenHealth Monroe, and WhidbeyHealth.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2002
Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 1997 - 2000
Hebei Medical University
Certifications & Licensure
WA State Medical License 2000 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- Rare presence of Charcot-Leyden crystals in acute myeloid leukemia.Sujan Badal, Mahnoosh Taheri, Peter Jiang, Kirstine Oh
European Journal of Haematology. 2023-10-01 - 48 citationsAdvances in targeted therapy for acute myeloid leukemiaJifeng Yu, Peter Y. Z. Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang
Biomarker Research. 2020-05-20 - 11 citationsPhase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patientsSaul E. Rivkin, James Moon, Desiree Iriarte, Erik Bailey, Heather L. Sloan
International Journal of Gynecological Cancer. 2019-01-29
Professional Memberships
- Member
